This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Silverstein, J. H. Articles by Rosenbloom, A. L. Search for Related Content PubMed PubMed Citation Articles by Silverstein, J. H. Articles by Rosenbloom, A. L. Social Bookmarking                   What's this?

New Developments in Type 1 (Insulin-Dependent) Diabetes

Division of Endocrinology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida; Children's Medical Services Center, 1701 SW 16th Avenue, Gainesville, Elorida 32608

Arlan L. Rosenbloom, MD

Division of Endocrinology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida

The Diabetes Control and Complications Trial has conclusively demonstrated that improved metabolic control leads to reduction in the rate of microvascular complications of diabetes. In order to allow patients to achieve improved metabolic control, much research has focused on improved methods of glucose monitoring and more physiologic ways of insulin delivery. The 2 most promising methods of minimally invasive blood glucose monitoring are the Glucowatch, using the technique of reverse iontophoresis to measure interstitial fluid glucose levels every twenty minutes and an implantable sensor, in which a catheter resembling that used for insulin delivery through a pump is impregnated with glucose oxidase at the tip. This device monitors blood sugars every few minutes, but like a holter monitor, must be downloaded in the physician's office. Still under development are (1) implantable subcutaneous sensors with a high and low blood glucose alarm and (2) sensors in which the patient will be able to download the data using a home PC. Advances in insulin delivery have included the availability of new insulin analogs which more closely simulate endogenous insulin release, with rapid acting analogs simulating the increase in insulin production that normally occurs after meals. Phase III clinical trials are in progress of a long-acting basal insulin without peak actions to simulate the low dose continuous production of the insulin which normally inhibits hepatic glucose production. In addition, use of the insulin pump has increased markedly since publication of the DCCT with the greatest increase being among adolescents. In addition to advances in treatment of diabetes, research has continued on curing the disease using islet cell transplantation and preventing the disease with agents such as insulin (DPT-1 Trial) and nicotinamide (ENDIT). This article provides an overview of recent advances in diabetes management and prevention.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. H. Johnston-Brooks, M. A. Lewis, and S. Garg Self-Efficacy Impacts Self-Care and HbA1c in Young Adults With Type I Diabetes Psychosom Med, January 1, 2002; 64(1): 43 - 51. [Abstract] [Full Text] [PDF]